[An experience of the application of rispolept in childhood schizophrenia].
The efficiency of rispolept was examined in open non-comparative study which included 32 patients 6.5-16 years of age with schizophrenic spectrum disorders. Efficiency of the drug was estimated by clinical psychopathologic method together with the evaluation according to the PANSS. 5 patients were additionally estimated according to the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) for the obsessive-compulsive disorders (a children version). The drug was used during 6 weeks in therapeutic doses from 4 to 8 mg/day. Reduction of the symptoms was 42% according to the PANNS for the positive items and 39% for the negative ones. There was also a significant decrease of manifestations of the obsessive-compulsive symptomatology according to CY-BOCS and of the depressive symptomatology according to the PANSS. Side effects comprised by vasotonic reactions (2 cases), oculomotor (2 cases) and torsion (one case) dyskinesias, which quickly disappeared after the correctors' administration. Extrapyramidal disorders were observed only after the increase of the dose up to 6-8 mg/day (3 cases). Results of the study have shown a high therapeutic efficiency of rispolept for childhood schizophrenia.
Kozlova
I A
IA
Burelomova
I V
IV
Goriunov
A V
AV
Grebchenko
Iu F
IuF
Masikhina
S N
SN
D000293:Adolescent; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000150:complications / Q000175:diagnosis / Q000523:psychology; D018967:Risperidone / Q000008:administration & dosage / Q000627:therapeutic use*; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D018967:Risperidone
Opyt primeneniia preparata rispolept pri shizofrenii detskogo vozrasta.